Discovery On Target 2014 | Development of Histone Demethylase Inhibitors

from CHI Podcasts · host Cambridge Healthtech Podcasts

As a preview to Discovery on Target 2014, Cambridge Healthtech Institute’s Kip Harry speaks with Dr. Tamara Maes on recent advancements in LSD1 Inhibition, including the current status of Oryzon Genomics’ ORY-1001 trial, in collaboration with Roche. Dr. Tamara Maes will be discussing this in more depth at Discovery on Target’s Targeting Histone Methyltransferases and Demethylases Conference. Learn more at http://www.discoveryontarget.com/Histone-Methyltransferases

Episode metadata supplied by the publisher feed · Published Sep 4, 2014

Embed this episode

Attribution link and audio player

NOW PLAYING

Discovery On Target 2014 | Development of Histone Demethylase Inhibitors

0:00 14:35

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of CHI Podcasts?

This episode is 14 minutes long.

When was this CHI Podcasts episode published?

This episode was published on September 4, 2014.

Can I download this CHI Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!